{"id":"NCT03673943","sponsor":"Radiomedix, Inc.","briefTitle":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","officialTitle":"An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedixâ„¢) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-23","primaryCompletion":"2019-03-23","completion":"2019-08-07","firstPosted":"2018-09-17","resultsPosted":"2022-12-22","lastUpdate":"2022-12-22"},"enrollment":63,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Neuroendocrine Tumors"],"interventions":[{"type":"DRUG","name":"64Cu-DOTATATE","otherNames":["NETMEDIX"]}],"arms":[{"label":"PET/CT imaging with 64Cu-DOTATATE","type":"EXPERIMENTAL"}],"summary":"This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.","primaryOutcome":{"measure":"Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) Tumor","timeFrame":"12 months","effectByArm":[{"arm":"PET/CT Imaging With 64Cu-DOTATATE","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["31924723"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":63},"commonTop":["vomiting (both grade 1)","nausea (grade 1)","headache (grade 1)","syncope (grade 2)","melanoderma (grade 1)"]}}